PIK3CA and head and neck squamous cell carcinoma: We then sought to correlate these findings in vivo using a patient-derived xenograft (PDX) model of PIK3CA-mutated HNSCC, named H22, by testing the efficacy of therapy combinations of BYL719 or GDC0032 with RAD001 or abemaciclib, respectively (Figure 3c,d).